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Background: The purpose of this paper is to describe the 
establishment of the Advanced Clinical Monitoring of ART Project 
in Ethiopia for monitoring and evaluation of the longitudinal 
effectiveness of the ART program and to show the opportunities it 
presents. This cohort was established in response to the 2005 call 
by WHO for establishing additional mechanisms for stronger 
monitoring of ART and the need for creating the platform to 
generate evidence to guide the care given for the ever increasing 
number of patients on ART in Ethiopia.  
Method: A participatory and multi-stage process which started 
from a consensus building workshop and steered by a mother 
protocol as well as guiding documents which dictated the degree of 
engagement and expectations was followed. The primary and 
secondary aims of the study were agreed upon. A multi-site 
longitudinal observational clinical cohort was established by a 
consortium of stakeholders including seven Ethiopian medical 
schools and their affiliated referral hospitals, John Hopkins 
University, Ethiopian Public Health Institute, Ministry of Science 
and Technology, US Centers for Disease Prevention and Control - 
CDC-Ethiopia, and the Federal Ministry of Health. Adult and 
adolescent cohorts covering the age range of 14+ years) and 
pediatric cohorts covering those below age 14 years were the two 
main cohorts. During the initial recruitment of these cohorts 
information was extracted from existing documents for a total of 
2,100 adult participants. In parallel, a prospective cohort of 1,400 
adult and adolescent patients were enrolled for ART initiation and 
follow-up. Using similar recruitment procedures, a total of 120 
children were enrolled in each of retrospective and prospective 
cohorts. Replacement of participants were made in subsequent 
years based on lost follow up and death rates to maintain adequacy 
of the sample to be followed-up.   
Achievements: Between January 2005 and August 2013 a total of 
4,339 patients were followed for a median of 41.6 months and data 
on demographic characteristics, baseline and ongoing clinical 
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features, hospitalization history, medication and 
laboratory information were collected.  39,762 
aliquots and 25,515 specimens of plasma and dry-
blood-spots respectively were obtained and stored 
longitudinally from October 2009 to August 2013. 
The project created a research platform for 
researchers, policy and decision makers. 
Moreover, it   encouraged local and international 
investigators to identify and answer clinically and 
programmatically relevant research questions 
using the available data and specimens. Calls for 
concept notes paired with multiple trainings to 
stimulate investigators to conduct analyses further 
boosted the potential for doing research.  
Conclusions: A comprehensive and resourceful 
mechanism for scientific inquiry was established 
to support the national HIV/ART program. With 
meaningful involvement and defined roles, 
establishment of a study, which involved multiple 
institutions and investigators, was possible. Since 
ACM is the largest multi-site clinical cohort of 
patients on antiretroviral treatment in Ethiopia---
which can be used for research and for improving 
clinical management---considering options to 
sustain the project is crucial.  
Key Words: Ethiopia, HIV clinical cohort, 
Antiretroviral therapy, Establishing Longitudinal 




The Ethiopian government began a limited program 
of making antiretroviral therapy (ART) available for 
a fee in 2003(1).  In early 2005, ART was made 
available nationwide without payment, with support 
from the Ethiopian government, the U.S. President’s 
Emergency Program for AIDS Relief (PEPFAR), 
and the Global Fund to Fight AIDS, Tuberculosis 
and Malaria(2).  
The prevalence of HIV in 2014 was 1.2% (3) and 
the incidence rate was reported as 15,000  by 
2016(4).With 79.0% coverage of eligible patients, 
Ethiopia had put 492,649 patients on ART by the 
end of 2013(5). The PEPFAR program provided 
technical and financial assistance to support the 
rapid nation-wide scale up of free ART(6). Ethiopia 
used the WHO consolidated guideline of ART for 
treatment and preventing HIV infection (7)
 
The introduction of free ART was paired with 
introduction of monitoring and evaluation (M&E) 
tools(8) to routinely track key program performance 
and outcome indicators. This routine M&E system 
provided limited and primarily aggregated 
information about the effectiveness of antiretroviral 
treatment.  The data were not sufficiently detailed to 
explore important demographic, clinical, laboratory 
or pharmaceutical determinants of treatment 
effectiveness.  
Moreover, a WHO consultation on 
development of a Standardized ARV Treatment 
Outcome Monitoring System held in October, 2005 
called for the development of a standardized 
outcome monitoring system that would provide 
additional information on treatment program 
success at facility, subnational and national levels. 
Consequently, a study allowing the detailed 
monitoring of a cohort of patients participating in 
the national free ART program at the referral 
hospitals of seven Ethiopian university medical 
schools was initiated. The Advanced Clinical 
Monitoring of ART in Ethiopia study (ACM ) was 
designed to provide the platform for advanced 
monitoring of the ART program in Ethiopia..  
Longitudinal cohort studies of HIV/AIDS 
patients in a clinic setting have been critical in 
fostering our understanding both of the natural 
history of HIV disease and of the effectiveness of 
treatment in a real-world setting.  
The purpose of ACM was to provide 
comprehensive data about the study cohort, and to 
make these data available to health care providers, 
hospital and clinic managers, researchers, national 
and regional health officials and other policy 
makers, enabling on-going improvements in 
prevention and treatment of HIV in Ethiopia based 
on critical analysis of data/specimens through 
research.     
The objectives of the ACM included the 
following: supporting the Ethiopian antiretroviral 
treatment program with the intention of  improving 
ART delivery by establishing a multi-site patient 
registry, cohort database and specimen repository, 
supporting the successful implementation of ART 
programs at each participating hospital by providing 
information that enable better patient level care, and 
clinic management; and, supporting the national 
ART program by providing detailed information 
about care processes, treatment adherence, virologic 
indicators and patient outcomes from the selected 
sites. The project also intended to facilitate 
operational research to refine national and 
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The cohort establishment process, began from a 
consensus building workshop with participation of 
the collaborating institutes and others who were 
involved in HIV care and treatment. The primary 
and secondary aims of the study were defined in this 
meeting. The primary aims included: (a) evaluation 
of treatment effectiveness, (b) assessment of 
monitoring protocols, (c) assessment of adverse 
effects of treatment, (d) assessment of adherence, 
and, (e) insight into potential causes of early 
mortality.  The secondary aims included: (a) 
assessment of guideline compliance, (b) monitoring 
of drug resistance development, (c) assessment of 
the impact of PMTCT on treatment effectiveness, 
(d) assessment of utilization rates for various kinds 
of care, and (4) an assessment of access to ART 
care.  
The study design of ACM was an ambi-directional 
follow up study which included retrospective data 
abstraction  and prospective data collection. Its 
establishment required site-specific follow up 
cohorts, and a governance structure with supporting 
documentation and legal backing. The following are 
the key approaches followed in establishing this 
clinical cohort.  
 
Structure and Governance:  
 
The seven Ethiopian medical faculties with their 
affiliated hospitals,  and five participating 
institutions, agreed to collaborate in the 
development, management and governance of the 
ACM project (Figure 1).  The collaborating 
institutions were: 
1. The Federal Ministry of Health of Ethiopia  
through the HIV/AIDS/STIs Prevention and 
Control Program (HAPCO) 
2. Addis Ababa University/Tikur Anbessa 
Hospital (AAU) 
3. National Defense University/Armed Forces 
Teaching General Hospital (NDU) 
4. Gondar University/Gondar University Hospital 
5. Jimma University/Jimma University 
Specialized Hospital 
6. Hawassa University/Hawassa University 
Referral Hospital 
7. Haramaya University/ Hiwot Fana Hospital 
8. Mekelle University/Mekelle Hospital 
9. The Ethiopian Public Health Institute (EPHI, 
formerly called “Ethiopian Health and 
Nutrition Research Institute” or EHNRI) 
10. Ministry of Science and Technology (formerly 
called “Ethiopian Science and Technology 
Commission” or ESTA) 
11. The Johns Hopkins University – Bloomberg 
School of Public Health (JHU) 
12. The United States Centers for Disease Control 
& Prevention (CDC- Ethiopia). 
 
   
Figure 1: Advanced clinical monitoring (ACM) project organization, January 1, 2005 to August 31, 2013, 
Ethiopia ACM.  
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The organizations agreed to work under a 
Memorandum of Understanding (MOU) with a 
Steering Committee making key decisions and 
providing guidance, and a Project Implementation 
Office (PIO) (located at  EPHI) overseeing day-to-
day implementation of activities. 
Each stakeholder had designated 
responsibilities, as stipulated in the MOU, to 
achieve the common goal of the project. The seven 
Ethiopian universities and their respective hospitals 
were considered as study sites because these 
facilities were engaged in provision of HIV care 
services including ART, and followed a high 
volume of patients. Moreover, they were located in 
geographically distant places covering a wide 
catchment population of the country, and were 
equipped with infrastructure and research centers.  
Site level offices were established in the ART 
clinics of the hospitals to manage data extraction, 
data entry, enrollment and data as well as specimen 
collection. There were 3 employees (Site Study 
Coordinator, Data Manager and Junior Data 
Manager) serving the ACM project in each of the 
seven sites. 
The other stakeholders included: (a) Ethiopian 
Federal Ministry of Health represented by the 
HIV/AIDS/STIs Prevention and Control 
Program/HAPCO (HAPCO was the owner of the 
national HIV program and responsible for guiding 
the National ART Program), (b) The Federal 
Ministry of Science and Technology provided 
regulatory guidance, (c) The Johns Hopkins 
University Bloomberg School of Public Health 
through a CDC-funded project in Ethiopia called the 
Technical Support for the Ethiopian HIV/AIDS 
ART Initiative (TSEHAI) served as the  PIO, to 
providing technical guidance and support to the 
national program, regional health bureaus, and 
hospitals and clinics participating in the free ART 
program, (d) CDC-Ethiopia was the funding 
agency, (e) The Ethiopian Public Health Institute 
(previously known as Ethiopian Health and 
Nutrition Research Institute - EHNRI), was the hub 
of the collaboration where the central data and 
specimens were kept and the coordination office 
was stationed (see Fig 1 and 2).  
 
 
Fig 2.  Specimen and Data Flow of the advanced clinical monitoring (ACM) project, January 1, 2005 to 
August 31, 2013, Ethiopia. Specimens from the 2 sites in Addis Ababa were being sent same day as 
collected and those from out of Addis were being sent within 2 weeks after partial processing.  
Note: communication was bidirectional with the intent of ensuring quality of data and specimens.  
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Organization of the project - Each collaborating 
institution signed an MOU, and a letter of support 
was provided by the funding agency (CDC).  
According to the MOU, a Steering Committee, 
formed by members selected from each 
participating institution, was the governing body of 
the consortium. The Steering Committee was 
composed of representatives who were elected by 
the member institutions.  The Steering Committee 
was governed by a bylaws. There were sub-
committees which served specific purposes. The 
Steering Committee had standing meetings on a 
quarterly basis. Extra-ordinary meetings were held 
as deemed necessary. The establishment of the 
collaboration through the signing of the MOU was 
accomplished over a period of two and a half years.  
An umbrella study protocol was also developed 
during this period and was approved by the national 
research ethics review committee under the 
Ministry of Science and Technology and the 
Institutional Review Boards of EPHI and the Johns 
Hopkins University Bloomberg School of Public 
Health, as well as the science office of CDC.  
Several amendments to the umbrella protocol were 
made during the follow up time and approved by the 
different ethics committees to address emerging 
issues with the most recent version of the umbrella 
protocol being version 4.0.  
The day-to-day activities of ACM were 
managed by the PIO under the directions of the 
Steering Committee.  An electronic data 
management system was created by the PIO. The 
database included seven-site level databases and a 
central database at EPHI where clinical and 
laboratory data from the seven sites were merged, 
cleaned and stored for analytic use.   
Specimen collection and storage mechanism 
was also established which included central storage 
in -80 degree Celsius deep freezers at EPHI. Data 
collection and data quality assurance activities were 
handled by study-site level study staff who worked 
at the seven hospitals. These staff were employed 
by the project and supervised by the PIO. They 
were expected to work collaboratively with staff 
members of the clinics, laboratories and 
pharmacies. All study sites had office space 
dedicated for ACM. The specimen collection was 
done by the hospital laboratory staff and in return 
they were receiving payment for the additional 
activities of collecting, processing and shipping of 
specimens related directly to the ACM study.  
Since ACM project was created as a research 
platform for scientific inquiries, mechanisms to 
encourage and enhance the practice of research 
were put in place. 
One mechanism included calls for concept 
notes. The calls were disseminated widely and the 
Research and Scientific Inquiry Sub-committee, 
working under direction of the main Steering 
Committee, reviewed concept notes and protocols, 
and guided researchers to align concept 
notes/protocols with the primary and secondary 
aims of ACM and to focus research questions on 
relevant and high priority areas for the national 
ART program.  The key functional units in 
facilitating the actual implementation of this were 
the PIO and the host institution.  
 
Daily Implementation – having a governance 
structure, some guiding documents and a mother 
protocol was not considered sufficient for 
smooth running. An office responsible for the 
actual execution was needed. Since the recipient of 
the funding was JHU, it was tasked to establish the 
PIO which was mandated to oversee the daily 
activities. The PIO had dual reporting lines – to the 
Steering Committee and to the JHU-TSEHAI 
project office.  
 
Host Institution for data and specimen – Since the 
seven participating local institutions were all 
interested in being the host, a mechanism for fair 
selection had to be established. The Steering 
Committee agreed on the following criteria to select 
the host institution: mandate (does the institution 
have a related mandate relevant to ACM?), 
neutrality (is the institution free of conflict of 
interest?), location (accessible to most participating 
institutions), potential to take over (able to maintain 
the cohort after external funding phased out), 
utilization potential (which institution can use the 
data and specimens optimally?) and management 
capacity (which institution can manage the project 
more resourcefully?). EPHI was selected as the host 
institution because it was the research arm of the 
Federal Ministry of Health, with unique technical 
and physical capabilities to handle the biological 
data, while at the same time was neutral to all 
contributing institutions.   
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Epidemiological Cohort Development:  
 
The two primary cohorts of ACM were 1) an adult 
and adolescent cohort, and 2) a pediatric cohort, 
created by considering age during the consent 
process. The primary cohorts were each sub-divided 
into database and repository cohorts. While data 
were collected on both cohorts, plasma and DBS 
specimens were collected every six months only 
from participants in the repository cohort. The 
ACM enrolled a group of initial patients and then 
recruited subsequent replacement participants each 
year.  The number of replacement participants was 
determined based on the number of participants lost 
to follow up and the number of cohort members 
who died in the previous calendar year. Each cohort 
had a retrospective period (data collected from 
active participants collected prior to enrollment) and 
a prospective period (data collected from active 
participants during enrollment and onwards) (Table 
1).  
 
Table 1:   Total number of participants enrolled in advanced clinical monitoring (ACM) project by study-






Adults (Age> 14) Children (Age <14) 
Addis Ababa University Tikur Anbessa Hospital 573 63 
National Defense University Armed Forces General Hospital 558 41 
Gondar University Gondar Referral Hospital 620 65 
Jimma University Jimma Referral Hospital 544 49 
Mekelle University Mekelle Referral Hospital 590 54 
Haramaya University Hiwot Fana Referral Hospital 535 49 
Hawassa University Hawassa Univ. Referral Hospital 542 56 
Total 3,962 377 
Adult and Adolescent Cohort (Age >14 years) - 
The initial group of participants (400 per site) 
enrolled in this cohort were divided into existing 
(ART-experienced) and new (ART-naïve) groups. 
A total of 300 ART experienced participants were 
sampled from a registry of patients receiving ART 
care at each site. In addition, 100 ART-naïve 
patients were recruited prospectively to constitute 
the initial cohort. Subsequently, each study-site 
planned and enrolled on a replacement basis, to 
ensure representativeness, a total of at least 60 new 
participants in a given calendar year per the 
protocol. 
 
Pediatric Cohort (Age < 14 years) - The initial 
group of participants (40 per site) enrolled in this 
cohort were divided into existing (ART-
experienced) and new (ART-naïve) groups. A total 
of 200 ART experienced participants were sampled 
from a registry of patients receiving ART care in the 
study sites. In addition, 20 ART-naïve patients were 
recruited prospectively to constitute the initial 
cohort. Subsequently, each site planned and 
enrolled on a replacement basis, to ensure 
representativeness, a total of at least 10 new 
participants in a given calendar year. 
 
Adult and Adolescent Repository Cohort (Age >14 
years) - The initial group of participants (100 per 
site) were enrolled prospectively into the adult and 
adolescent repository cohort. Each site sought to 
recruit all eligible participants from the Database 
Adult and Adolescent Cohort at their ART initiation 
visit immediately following their consent to 
participate in the database cohort. Once the site 
reached a total of 100 participants, subsequent 
enrollment was on a replacement basis as sample 
size fell below 100.  
  
Pediatric Repository Cohort (Age <14 years) -  The 
initial group of participants (20 per site) were 
prospectively enrolled into the pediatric repository 
cohort. Each site sought to recruit all eligible 
participants from the Database Pediatrics Cohort at 
their ART initiation visit immediately following 
their consent to participate in the database cohort. 
Once the site reached a total of 20 participants, 
subsequent enrollment was on a replacement basis 
as sample size fell below 20.   
 
Participant Enrolment and Follow up - Site level 
enrollment and data/specimen collection activities 
were done according to standard operating 
procedures. All patients who initiated ART on or 
after January 1, 2005 were eligible for enrollment 
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regardless of their status at the time of enrollment. 
Given the retrospective nature of some of the data, 
the sampling frame included patients who had died 
by the time the study began. All enrolled 
participants were given unique identifiers and 
random selection was done so that all eligible 
patients had equal chance of being approached for 
enrollment 
Patients who were alive and randomly selected 
as potential participants were approached when they 
came for their routine visit and, in a confidential 
setting, asked if they wanted to provide informed 
consent to participate in the ACM. If a participant 
agreed to participate in ACM, they signed a consent 
form and were enrolled in the database cohort. 
Parental consent was obtained for those pediatric 
participants <10 years of age and those older than 
10 years of age, in addition to the written parental 
consent, a verbal assent was also obtained from the 
children. Participants were compensated for their 
time. If patients declined to participate, the next 
eligible patient was approached. Participants 
enrolled in only the database cohort were expected 
to provide data during their routine follow up visits; 
while those enrolled in both the database and 
repository cohorts were expected to come to the 
facility for routine visits and provide specimens 
every six months.  
 
Sample selection and size determination -  
Retrospective cohort participants were selected 
randomly from the list of all potentially eligible 
registered patients from the ART database. All 
participants were given an equal chance of being 
selected.  A computer program using uniform 
distribution was applied to generate random 
numbers to select study participants. A total of 
2,100 ART experienced participants were selected 
from the seven sites. Prospective cohort participants 
were selected randomly at ART initiation until the 
required sample size was reached. 
The sample size for cohort development was 
determined considering the available resources and 
multiple analyses and research topics raised by 
investigators. Various intra cluster correlation 
coefficient (ICC) values were considered for site 
comparison. Hence a total of 2,800 adults, with 700 
participants in repository cohort, and 280 pediatric 
participants, with 140 in the repository cohort, was 
considered a sufficient sample size to answer 
project objectives.  
   
Data and Specimen Management Information 
System Development:  
 
Data on clinical and demographic characteristics, 
ongoing medical care, and clinical and laboratory 
outcomes were collected on all participants in the 
cohort. Plasma specimens were also obtained and 
stored every six months for viral load and resistance 
testing, and for other studies to be specified on 
subsamples of the overall cohort.  
The project used the National ART forms 
(ART intake forms, ART follow up forms, 
laboratory and Pharmacy Drug Dispense form) and 
ACM specific forms (Patient Information form 
(PATI), Outpatient care (OCARE), Outpatient 
Clinical Laboratory Abstraction form (OCLA), 
Tuberculosis abstraction form (TB), Hospitalization 
form (HOSP), Visit form (VIST), Termination 
(TERM), Mortality form (MORT), Maternity Data 
Abstraction form (MATR) and Specimen Collection 
and Processing form (SCPF). ACM specific 
instruments were pre-tested and modifications made 
regularly through version control. 
Except for specimen collection purposes with 
specific appointments and corresponding coverage 
of transportation expenses, patient visits were 
limited to the required clinical visits for routine care 
and no study-specific appointments were given to 
patients.  
Antiretroviral Treatment Information System 
for Ethiopia (ARTISE), an ACCESS-based 
database, was deployed at each participating site to 
collect patient data. ARTISE functionality included 
a data entry template, patient tracking, database 
backup, generating ad hoc reports and de-
identification programming. The De-identification 
process eliminated patient identifiers information 
like names, address, medical card numbers, and all 
possible combination keys, etc. before data 
extraction and transportation. The ARTISE system 
linked the unique ACM ID number with a one to 
one function to all participants so that data and 
specimen users were blinded while accessing the 
resources centrally. On a quarterly basis, a de-
identified ARTISE backup was transported to 
Ethiopian Public Health Institute to be consolidated 
and stored in a SQL-based Central Database (CDB). 
CDB was created through a structured process of 
requirements, specification, design, implementation, 
testing, and deployment. The functions of the CDB 
included ARTISE site data consolidation, provision 
of coding guide for each exported data field, 
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laboratory information management for specimens, 
analytical dataset export, and built-in and ad-hoc 
reporting (Fig 3).  
 
Figure 3: Data and specimen flow to central data and specimen warehouse at Ethiopian Public Health 
Institute (EPHI), January 1, 2005 to August 31, 2013, Ethiopia. All de-identified data was gathered in the 
central database, a SQL server based system developed specifically for this purpose.  
 
Laboratory Management  - As shown in Figure 2, 
specimens were collected from all ART naïve 
repository participants at the time of enrollment and 
every 6 months thereafter for 24 months; 
subsequent specimen collections were every 12 
months. With the exception of Addis Ababa sites 
(Tikur Anbessa and Armed Forces Hospitals), 
plasma and DBS specimens were collected, 
processed and transported from each site to EPHI 
on a bi-monthly basis.  
All whole blood specimens collected from 
participants in sites outside of Addis (5 out 7 sites) 
were used to provide Dried Blood Spots (DBS) and 
the remaining were processed into plasma aliquots 
and stored temporarily on site at -20-degree freezer. 
The processed plasma aliquots and DBS were 
shipped to the central repository at EPHI within 15 
days of collection. All plasma specimens were 
transported using dry ice to maintain the cold chain.  
Whole blood specimens collected from participants 
in the Addis sites (2 out 7 sites) were transported 
within six hours of collection to EPHI for further 
processing into DBS and plasma aliquots. All 
specimens received at the central repository in EPHI 
were counterchecked with corresponding 
documentation to ensure accuracy and timeliness 
and were permanently stored in -80 
0
C deep 
freezers.  In addition to storing the merged site 
datasets, the SQL-based central database also stored 
the repository database and mapped all the 
specimens for easy retrieval.  
 
Data Preparation and Analysis-  In general, 
customized datasets were prepared for researchers 
based on variables needed to answer their research 
questions. Data cleaning and preparation of datasets 
were the mainstay of the data management unit. An 
overall descriptive analysis  of the patients in the 
database is provided in Table 2.  
 
Ethical review:  
 
Given the fact that multiple Ethiopian universities, 
JHU and CDC had their own institutional review 
boards (IRBs), approval at multiple levels appeared 
to be required. To expedite the process, the EPHI 
institutional review board was designated to 
represent all the local university IRBs. Following 
the review and approval from the EPHI IRB, the 
protocol was simultaneously submitted to the 
National Research and Ethics Committee at the 
Ministry of Science and Technology in Ethiopia, the 
IRB at Johns Hopkins University Bloomberg 
School of Public Health, and the science office of 
the CDC.  
This process, with parallel review by three 
different institutions, with different time intervals 
for review, where each of the IRBs could require 
changes that then needed to be re-reviewed, delayed 
the initiation of the study. Final clearance was 
secured nine months after submission of the first 
version of the ACM protocol. Another challenge 
that further prolonged the review process was the 
gap in the Ethiopian Research Ethics Guidelines 
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regarding use of data obtained from patients who 
were already dead or who were lost to follow up 
and could not be tracked to seek informed consent. 
This lack of guidance led to multiple consultative 
meetings between the research team and the 
National Research Ethics Committee to reach 
consensus. While the study was allowed to use data 
from patients who had died, the IRB was not willing 
to allow inclusion of patients who were not in 
follow up and whose final status was unknown.  
ACM secured required approvals for 




After three years of preparatory work, the ACM 
project initiated enrollment in 2009. As shown in 
Table 1 and Figure 4, a total of 3,962 adults and 377 
children were enrolled in the study. The sites had 
comparable contributions with a mean of 566 adults 
(542-620) and 54 children (41-65) per site.  
ACM provided collaborators the opportunity to 
form a research consortium which involved seven 
local universities, one international university, 
CDC, the Ministry of Science and Technology, the 
Ethiopian Public Health Institute and the Ministry 
of Health. To the best of our knowledge ACM 
continues to be the largest research collaboration in 
the country.  In addition to the fact that it serves as a 
platform for national and international 
collaboration, the lessons learned in terms of 
processes for establishing a large multi-site cohort 
study are worth discussing.  
 
Figure 4: Advanced clinical monitoring (ACM) multisite database and repository cohort enrollment by year, 
January 1, 2005 to August 31, 2013, Ethiopia. 
 
As  summarized in Table 2 and 3a, among the 
adults, 62% (n=2,452) were female and 38% 
(n=1,510) were male. Most of the participants were 
in the 25-39 year age category, and only 10% were 
older than 50 years. At the time of enrollment, the 
majority of the study participants (57%) had a 
baseline CD4 count of 50-200 and more than 66% 
of the participants were in WHO stage 3 and 4.  
At initiation of treatment, the most commonly 
prescribed NRTIs for retrospective cohort patients 
were AZT (38%) and d4T (33%). In 2009, 
following the introduction of Tenofovir, the trend 
changed to TDF as the most prescribed NRTI 
(53.6%). Efavirenz (EFV) and NVP were the only 
NNRTIs prescribed, with NVP accounting for 
56.5%. Cotrimoxazole prophylactic treatment 
(CPT) was prescribed to more than 90% of the 
patients, but INH was given to only 4% (n=160). 
TB treatment was initiated for 15.4% (n=604) of 
patients. As seen on table 3b, with a total of 39,762 
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aliquots and 25,515 DBS, a large pool of specimens 
was created. The mean follow-up period of patients 
on ART was 44 months with median follow-up of 
41.6 months.   
The project conducted workshops and 
advanced data analysis trainings for participating 
university investigators to support their studies and 
answer relevant scientific inquiries using available 




Table 2: Patient Characteristics of advanced clinical monitoring (ACM) participants at ART initiation, 
January 1, 2005 to August 31, 2013, Ethiopia. 
 
* There are some missing values 
Adult and Adolescent Multisite Cohort  Pediatrics Multisite Cohort 
Variables n (%) Variables n (%) 





















18-19 23 (0.58%) 
1-4 102(27.06%) 
20-24 215 (5.43%) 
25-29 766 (19.33%) 
5-9 196(51.99%) 
30-34 877 (22.14%) 





40-44 507 (12.80%) 
45-49 303 (7.65%) 










<100 10 (3.41%) 
50 - 200 2,193(57.30%) 50 - 200 86 (29.35%) 
200 - 350 992 (25.92%) 200 - 350 97 (33.11%) 
350 - 500 48 (1.25%) 350 - 500 39 (13.31%) 








Ambulatory 882(22.73%) Delay 164(48.38%) 












WHO stage I 32 (8.70%) 
WHO stage II 823 (21.14%) WHO stage II 101(27.45%) 
WHO stage III 1,961(50.37%) WHO stage III 168(45.65%) 











d4T+3TC+NVP 121 (5.6%) 





AZT+3TC+EFV 438 (11.06%) AZT+3TC+EFV 39 (10.40%) 
TDF+3TC+NVP 210 (5.30%) TDF+3TC+NVP 1 (0.03%) 
TDF+3TC+EFV 898 (22.67%) TDF+3TC+EFV 0 (0.00%) 
Other 38 (0.96%) Other 30(8.00%) 
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Table 3a:   Total number of participants enrolled in advanced clinical monitoring (ACM) project by cohort, 







Male Female  
Multisite Adult and 
Adolescent 
Database Cohort 1,125 1,855 2,980 
Repository Cohort 385 597 982 
Multisite Pediatrics  
 
Database Cohort 125 106 231 
Repository Cohort 69 77 146 
 Total 1,704 2,635 4,339 
Table 3b:   Total number of samples collected by visit for repository cohort participant in advanced clinical 




Visits after ART Initiation for Repository Cohorts (months) 
M0 M6 M12 M18 M24 M30 M36 M42 Total 
Total number of 
aliquots stored 
8,762 6,985 6,290 5,756 5,128 4,056 2,429 356 39,762 
Total number of 
DBS spots collected 
5,640 4,465 3,995 3,650 3,295 2,595 1,615 260 25,515 
 
The ACM platform enabled researchers to 
determine predictors of survival among adults on 
ART (15), common causes of hospitalization and 
outcomes among pediatric patients on ART (16), 
magnitude of drug toxicity (17), timeliness of HIV 
care (18) and mortality of patients on ART with 
TB co-infection (19). Answers to more research 
questions are in the pipeline and the authors 
anticipate many more research activities based on 




Funding - Though this project was of national 
importance, it was solely funded by PEPFAR 
through CDC-Ethiopia. When the CDC funding 
came to an end, active follow up of participants 
and data and specimen collection were suspended. 
However, with the support of EPHI, use of the 
available data and specimens to address key 
research and programmatic questions is being 
encouraged and facilitated.  
 
Data use - Although the data and specimens were 
being analyzed to address research aims, little was 
done early on to support public health decision-
making, and therefore data and specimens were 
not likely to been used to their full potential.  
 
Specimen use - All research activities requiring 
use of specimens needed to come with associated 
funding. Except for the limited viral loads done 
through the CDC funding, no advanced tests have 
been done. The routine laboratory investigations 
including CD4, blood chemistry and other basic 
laboratory data are available at the facility level 
and results are documented and captured on the 
ACM database.  
 
DISCUSSION AND LESSONS LEARNED: 
 
Establishment of the ACM project responded to 
the need for an African cohort that would enable 
certain research questions to be addressed. The 
five-country study by Dalal et al.(13), reflected on 
the need for a longitudinal as opposed to cross 
sectional study, and the ACM Project 
demonstrates its feasibility. The retention rate at 
month 6 was more than 80 percent, which is 
higher than found by Dalal et.al (13). Publications 
showing the process of establishment of specific 
cohort studies are very scarce. 
There are over 30 large HIV cohort studies 
ongoing, according to the Forum for Collaborative 
HIV Research. Some of the largest are Euro-SIDA 
with 60 clinical centers in Europe, the Swiss HIV 
Cohort with 7 centers, and the HIV Research 
Network with 17 centers in the U.S.(10) However, 
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the vast majority of these multi-site cohort studies 
are being carried out in high resource settings –  
U.S., Europe and/or Australia. ACM has been able 
to stimulate generation of local evidence.  
Seven essential research questions were 
answered in the first round of research activity, 
and an additional 18 are in the pipeline.  
With more than 4,000 patients, ACM is larger 
than many of the cohort studies in Africa. The 
AFRICOS study has 3,600 patients. The multi-
centre prospective cohort network of pediatric 
clinics in West Africa, which involves seven 
countries, has 1,415 participants.  But it was 
comparable to the cohort study involving 3 
countries by Koole et al. which has 4,147 patients 
included though it was a retrospective cohort 
study (14) 
ACM is a multi-site clinical cohort with the 
potential to provide valuable information about the 
effectiveness of the ART program, the survival of 
patients on ART, incidence of ART-related 
toxicities, and other more research questions. The 
fact that ACM has readily available 
longitudinally-collected specimens with 
corresponding clinical and socio-demographic 
data makes it an ideal platform for researchers.  
Establishing and running a multi-site cohort study 
requires creation of a functional system that will 
guide the collaboration. A multi-site, multi-partner 
clinical cohort establishment also requires a long-
term commitment and advance planning for 
maintenance of the cohort.  
 
Establishing the cohort –Starting with a clear 
study purpose, and ensuring meaningful 
involvement of all stakeholders by creating the 
venue for consultative engagement, were crucial. 
Developing the rules of collaboration as well as 
defining the roles and responsibilities of each 
institution at the inception played a crucial role in 
building ownership. The discussion of how to 
integrate the implementation office and its 
functions, including the data and specimen 
warehousing within EPHI, gave ACM the chance 
to continue even after donor funding was 
discontinued. 
 
Maintaining the cohort - Since there are close to 
4,000 participants enrolled in ACM, and since 
there is a need for site level staff, maintaining 
follow up of participants at the ACM study sites 
would have required continued funding.  
However, given that all the structural issues were 
addressed, maintaining ACM was not significantly 
challenging.  Though enrollment have been 
suspended, we have learned that ACM has an 
invaluable pool of data and specimens which can 
be used to inform the ART program nationally, 
and HIV/AIDS research globally. 
 
Ethical clearance process - Though the process 
was not as fast as we desired, delegation of one 
IRB to be the local IRB on other institutions’ 
behalf expedited the process. Parallel submission 
of the protocol has also enabled somewhat faster 
clearance. 
 
Stimulating scientific inquiries - Posting calls for 
concept notes, followed by organizing consultative 
workshops gave investigators the chance to review 
scientific questions. Examination of data during 
the consultative workshops also helped in 
stimulating research by the busy clinicians.  
Limitations - The project was not able to start 
participant enrollment at the beginning of ART 
initiation in 2005, hence we were forced  to 
include a retrospective cohort design with the 
intention of understanding the early years of the 
ART program.  The transition away from donor 
funding was challenging and alternative funding 
mechanisms were not put in place by the time 
funding from CDC ended, resulting in suspension 
of the project.  
 
 
Future analyses - The findings of the 
aforementioned seven sub-studies have shown us 
that many important questions can be answered 
using the ACM cohort. Although additional 
research questions can be answered using the 
ACM data, it is strongly recommended that future 
studies be geared towards informing decisions of 
the national program, in addition to regional and 
global issues. More emphasis should be placed on 
timely availability and use of the data, on 
increased networking, and on creating strong 




 The findings and conclusions in this report are 
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represent the official position of the Centers for 
Disease Control and Prevention.  
 
Attribution/ Acknowledgement 
The Research has been supported by the 
President’s Emergency Plan for AIDS Relief 
(PEPFAR) through the Centers for Disease 
Control and Prevention (CDC) under the terms of 
Cooperative Agreement with Johns Hopkins 
Bloomberg School of Public Health number 
PS000858.  We would like to express our 
gratitude to the providers who routinely 
documented the status of their patients on the 
standard forms and last but not least, we would 
like to thank all the study subjects who consented 




The Research has been supported by the 
President’s Emergency Plan for AIDS Relief 
(PEPFAR) through the Centers for Disease 
Control and Prevention (CDC) under the terms of 
Cooperative Agreement with Johns Hopkins 





1. Ministry of Health of Ethiopia. Guideline for 
use of Anti Retroviral Drugs in Ethiopia 
FMOH, DACA and FHAPCO; 2003. 
2. Federal HIV/AIDS Prevention and Control 
Office. Country progress report on the HIV 
response; Report. 2014. 




November 3, 2015.  
4. Minstry of Health of Ethiopia.  Annual 
Performance Report EFY 2006 (2013/14). 
Addis Ababa: Federal Ministry of Health   
2013/14  Contract No.: 02/14. 
5. Ethiopian Public Health Institute. HIV related 
estimates and projections for Ethiopia; 
Report. 2012. 
6. PEPFAR. Ethiopia 2014 Country Operational 
Plan Executive Summary; 2014. 
7. World_Health_Organisation. Consolidated 
guidelines on the use of antiretroviral drugs 
for treating and preventing HIV infection: 
recommendations for a public health 
approach. Geneva, Switzerland2013. 
8. Federal HIV/AIDS Prevention and Control 
Office. National Monitoring and Evaluation 
Framework for the Multi-sectoral Response to 
HIV/AIDS in Ethiopia. Addis Ababa: 
FHAPCO; 2003. 
9. Monitoring the output and outcome of anti-
retroviral therapy (ART) programmes,  WHO, 
UNAIDS, and partners, Mövenpick Hotel, 
Geneva, 10-12 October 2005. 
10. World Health Organization, Progress on 
Global Access to HIV Antiretroviral Therapy: 
A Report on “3 by 5” and Beyond, March 
2006.   
11. AFRICOS Study, 2013; retrieved from: 
www.hirresearch.org/africos 
12. Arrive, E., Dicko, F. Amghar, H. Aka, A.E. 
Dior, H.Bouah, et.al. Pediatric IeDEA West 
Africa Working Group. (2012). HIV status 
disclosure and retention in care in HIV 
infected Adolescents on antiretroviral 
thearapy (ART) in wes Africa. PloS One, 
7(3),e33690.doi:10.1371/journal.pone.003369
0[doi] 
13. Dalal, S.Holmes, M.D, Laurence, C., 
BAjunirwe, F.,Guwatudde, D.,Njelekela, M., 
et.al. (2015). Feasibility of a large cohort 
study in sub-saharan Africa assessed through 
four-country study. Glob Health Action,8. 
14. Koole,O.,Tsui,S.,Wabwire-Mangen, F., 
Kwesigabo,G.,Menten,J.,Mulenda,M., et.al. 
Retention and Risk factors among adults in 
antiretorival treatment programmes in 
Tanzania, Uganda and Zambia. Tropical 
Medicne and Intenational Health:TM&IH, 
19(12, 1397-1410. 
doi:10.1111/tim.12386[doi]) 
15.  Daniel Fekade, Teklu Woldegebriel, Alula M. 
Teklu, Melake Damen, Saro Abdella, Neaga 
Baraki, et.al. Predictors of survival among 
Adult Ethiopian Patients in the National ART 
program at Sevent Univeristy Teaching 
Hospitals: A prospective Cohort Study, EJHS, 
V27i1.3, pp 63-71 
                         Ethiop J Health Sci.                   Vol. 27, Special issue No. 1                      March 2017 
  
DOI: http://dx.doi.org/10.4314/ejhs.v27i1.2S  
16 
 
16. Abraham Haileamlak, Tesfalem Hagos, 
Workeabeba Abebe, Loko Abraham, Henok 
Asefa, Alula M. Teklu. Predictors of 
Hospitalization among Children on ART in 
Ethiopia: a Cohort study. EJHS;27si1.2, PP 
39-52 
17. Esayas Kebede Gudina, Alula M. Teklu, Asres 
Berhan, Atsbeha Gebreegziabhier, Teshome 
Siyoum, Abiy Nega., et.al. Magnitude of 
Antiretroviral Drug Toxicity in Adult HIV 
patients in Ethiopian: A cohort study at seven 
teaching hospitals. EJHS, v27si1.2, PP 39-52 
18. Alula M. Teklu, Kesetebirhan Delele, Mulu 
Abraha, Bekele Belayhun, Esayas Kebede 
Gudina, Abiy Nega. Exploratory Analysis of 
Time from HIV Diagnosis to ART Start, 
FActors and effect on survival: A longitudinal 
follow sup study at seven teaching hospitals in 
Ethiopia, EJHS, V27i1.2, pp 17-28. 
19. Alula M. Teklu1*, Abiy Nega, Admasu  
Tenna Mamuye, et al. Factors Associated with 
Mortality of TB/HIV Co-infected Patients in 
Ethiopia, EJHS, V27i1.2, pp 29-38  
 
 
Contributors: The following investigators contributed to study design and project government. 
 
The following investigators contributed to manuscript preparation and/or revision: 
Alula Teklu (lead), Eyuel Tsegaye, Abrham Hailemelak, Daniel Fekade, William Weiss, Elham Hassen, 
Yifru Berhan, Andrea Ruff  
 
The following investigators contributed to data preparation and/or analysis: 
  Eyuel Tsegaye 
 
ACM Study Team: 
Addis Ababa University: Daniel Fekade MD, MSC, Teshale Seboxa MD 
Armed Force General Teaching Hospital: General Tesfaye Gidey 
Gondar University: Assefa Getachew MD, Sisay 
Jimma University: Abrham Hailemelak Professor of Pediatrics and Child Health  
Mekelle University: Tesfalem Hagos MD, 
Haramaya University: Melake Damena  
Hawassa University: Yifru Birhan MD, Professor of OBGYN 
Johns Hopkins University (JHU-TSEHAI): Alula M. Teklu, Rahel Adamu, Andrea Ruff, Solomon 
Zewdu, Nicole Simmons, William Weiss, Aida Abashawul, Daniel Assefa, Hana Abera, Elham Hassen, 
Eyuel Tsegaye, Dawit Lisanework, Lelisa Amanuel, Altaye Feleke, Tigist Nemera, Fikre Hailekiros, 
Yodit Worku, Melkam Assefa, Lulit Girma,  Filkad Jemal, Gelaye Worku, Rehmet Gashu, Alefe Meressa, 
Dawit Mulu,  Yisak Kassa, Lidya Tesfaye, Mulu Alemu , Zelalem Fiseha, Zeleke Alemu, Bizuayehu 
Teshome, Liyu Asrat, Haymanot, Yonas Sime, Genet Elias, Saro Abdella, Jemal Tadesse, Abel Mamo, 
Abiy Abebe, Wubante Taye 
Ethiopian Science and Technology Agency/Later Ministry of Science and Technology: Dr Yeman 
Teklai, Yohannes Sitotaw 
Ethiopian Federal Ministry of Health: Achamyeleh Alebachew, MD, Taye Tolera, MD, PHD 
Ethiopian Public Health Institute: Eshetu Lemma PHD, Almaz Abebe PHD, Desta Kassa PHD, Atsbeha 
Geberexiaber  
Center for Disease Control Ethiopia: Ashenafi Haile MD, Solomon Ahmed MD 
 
 
 
 
